Domain Associates

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through the development of highly sensitive tests that identify and characterize circulating tumor cells (CTCs) using minimally invasive blood samples. Founded in 2008, the company’s platform enables the profiling of single-cell phenotypes and genotypes, providing detailed information on biomarker expression levels, morphologic characteristics, and genetic changes. Epic Sciences offers the Oncotype DX AR-V7 Nucleus Detect test specifically for patients with metastatic castration-resistant prostate cancer, as well as biopharma solutions. The company collaborates with biotechnology and pharmaceutical firms, major cancer centers, and renowned research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and guide treatment decisions.

Fractyl Health Inc. is a medical technology company dedicated to developing innovative solutions for the treatment of metabolic diseases, particularly type 2 diabetes and obesity. The company specializes in a minimally invasive procedure known as Revita DMR, or duodenal mucosal resurfacing therapy, which rejuvenates the lining of the duodenum through hydrothermal ablation. This approach aims to remove excessive layers of the duodenal mucosa that accumulate due to unhealthy diets, thereby addressing the root causes of metabolic disorders. Founded in 2010 and based in Lexington, Massachusetts, Fractyl Health seeks to redefine the treatment landscape from chronic management to durable, disease-modifying therapies, ultimately enhancing patient health and reducing the burden on healthcare systems.

Axial Biotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. Utilizing a microbiome discovery platform, the company targets the gut-brain axis to create innovative therapies aimed at improving the quality of life for patients suffering from neurological conditions. Founded in 2013 and headquartered in Waltham, Massachusetts, Axial Biotherapeutics is in the clinical stage of its development, working to advance its pipeline of novel CNS therapeutics.

Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, focused on developing innovative therapies for viral diseases. Founded in 2018 by Abel De La Rosa, Douglas Mayers, and Idean Marvasty, the company is dedicated to addressing the needs of patients infected with Hepatitis B and Hepatitis D viruses. Its lead product, ATI-2173, is an oral drug candidate aimed at providing a potentially curative treatment for Hepatitis B virus infections. With a leadership team that brings a wealth of experience, Antios Therapeutics is committed to advancing its therapeutic solutions in the field of viral diseases.

Nobias Therapeutics is a biotechnology company dedicated to developing treatments for genetically-defined rare diseases in children. The company employs advanced technologies, including artificial intelligence and machine learning, to analyze genetic and tissue databases, which aids in identifying potential therapies. By automating and simulating various stages of the pre-clinical and discovery processes, Nobias Therapeutics aims to streamline the development of new medicines and diagnostics. Its focus on rare pediatric diseases underscores its commitment to addressing unmet medical needs and improving the health of affected infants.

Exalys Therapeutics is engaged in the development of innovative anti-inflammatory therapeutics aimed at addressing a variety of diseases that currently have significant unmet medical needs. The company is focusing on creating first-in-class therapies, with an initial emphasis on preventing postoperative delirium, a common complication among older surgical patients that can lead to adverse health outcomes. By targeting inflammatory disorders, including pain and renal dysfunction, Exalys aims to provide effective treatment options for conditions that are often serious and life-threatening, yet lack adequate therapies.

Seraphina Therapeutics, Inc. is a health and wellness company based in San Diego, California, founded in 2017. It focuses on developing therapeutic products aimed at treating age-related comorbidities and slowing the aging process to enhance longevity. The company specializes in evidence-driven consumer products, including fatty acid supplements, micronutrients, food fortifiers, and nutritional interventions. These offerings are designed to support cellular health, improve mood, lower caloric intake, and enhance fat metabolism, ultimately helping individuals counter the effects of aging and promote healthier lives.

Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company specializes in induced pluripotent stem cells (iPSCs) to create patient-specific cell therapies. Its product pipeline includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By combining genomic approaches with stem cell biology, Aspen Neuroscience aims to address significant unmet medical needs and modify the progression of Parkinson's disease through personalized and restorative treatments.

Omniome, Inc. is a biotechnology company based in San Diego, California, that specializes in developing a proprietary DNA sequencing platform aimed at providing high accuracy in clinical sequencing. Founded in 2013, Omniome utilizes its Sequencing By Binding technology to enhance nucleotide and DNA matching, leveraging the natural matching capabilities of polymerases. This innovative approach allows researchers to achieve accurate and rapid sequencing results while maintaining low costs. The company's ambition is to become a leading name in DNA sequencing, particularly in advancing cancer diagnostics and improving outcomes in clinical settings.

ChromaCode Inc., established in 2012 and based in Carlsbad, California, specializes in molecular diagnostics. The company develops innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) using technology licensed from Caltech. ChromaCode's core products are software, reagents, and assays that enhance the multiplexing capabilities of quantitative PCR (qPCR) instruments by fivefold. Additionally, they offer molecular assays and software for various applications such as personalized medicine and pharmaceutical research. One of their notable products is the HDPCR Tick-Borne Pathogen Panel, a multiplex PCR test detecting common tick-borne pathogens in a single assay. ChromaCode's technology focuses on improving signal processing from life science instrumentation, enabling cost-effective testing of multiple targets simultaneously while integrating into existing laboratory workflows.

Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company specializes in induced pluripotent stem cells (iPSCs) to create patient-specific cell therapies. Its product pipeline includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By combining genomic approaches with stem cell biology, Aspen Neuroscience aims to address significant unmet medical needs and modify the progression of Parkinson's disease through personalized and restorative treatments.

Truvian Sciences Inc. is a diagnostic company based in San Diego, California, focused on revolutionizing the blood testing industry. Incorporated in 2015, the company has developed an automated benchtop system that delivers lab-accurate results for a variety of health tests. Its comprehensive wellness panel includes commonly ordered routine blood tests such as complete blood count, metabolic panel, and lipid panel, all from a single sample. Additionally, Truvian's software system enables healthcare practitioners to efficiently deliver test results to patients through a user-friendly platform.

Axial Biotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. Utilizing a microbiome discovery platform, the company targets the gut-brain axis to create innovative therapies aimed at improving the quality of life for patients suffering from neurological conditions. Founded in 2013 and headquartered in Waltham, Massachusetts, Axial Biotherapeutics is in the clinical stage of its development, working to advance its pipeline of novel CNS therapeutics.

Singular Genomics is a life science technology company that develops innovative sequencing platforms. Its core product, the Singular Sequencing Engine, powers two integrated solutions: G4 for next-generation sequencing (NGS) markets, offering high accuracy and speed; and PX, which combines single-cell analysis, spatial analysis, genomics, and proteomics in one versatile multi-omics instrument. These products aim to empower researchers and clinicians across diverse fields such as basic biology, oncology, immunology, and more.

Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, focused on developing innovative therapies for viral diseases. Founded in 2018 by Abel De La Rosa, Douglas Mayers, and Idean Marvasty, the company is dedicated to addressing the needs of patients infected with Hepatitis B and Hepatitis D viruses. Its lead product, ATI-2173, is an oral drug candidate aimed at providing a potentially curative treatment for Hepatitis B virus infections. With a leadership team that brings a wealth of experience, Antios Therapeutics is committed to advancing its therapeutic solutions in the field of viral diseases.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing etripamil, a novel calcium channel blocker designed for the treatment of various cardiovascular conditions. Etripamil is a rapid-onset nasal spray intended for self-administration to terminate episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently conducting Phase III clinical trials for etripamil in the United States and Canada, specifically targeting PSVT, as well as ongoing Phase II trials for patients with atrial fibrillation experiencing a rapid ventricular rate. Founded in 2003 and headquartered in Montréal, Canada, Milestone Pharmaceuticals aims to address unmet needs in the treatment of transient cardiovascular conditions such as atrial arrhythmias and angina.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through the development of highly sensitive tests that identify and characterize circulating tumor cells (CTCs) using minimally invasive blood samples. Founded in 2008, the company’s platform enables the profiling of single-cell phenotypes and genotypes, providing detailed information on biomarker expression levels, morphologic characteristics, and genetic changes. Epic Sciences offers the Oncotype DX AR-V7 Nucleus Detect test specifically for patients with metastatic castration-resistant prostate cancer, as well as biopharma solutions. The company collaborates with biotechnology and pharmaceutical firms, major cancer centers, and renowned research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and guide treatment decisions.

Omniome, Inc. is a biotechnology company based in San Diego, California, that specializes in developing a proprietary DNA sequencing platform aimed at providing high accuracy in clinical sequencing. Founded in 2013, Omniome utilizes its Sequencing By Binding technology to enhance nucleotide and DNA matching, leveraging the natural matching capabilities of polymerases. This innovative approach allows researchers to achieve accurate and rapid sequencing results while maintaining low costs. The company's ambition is to become a leading name in DNA sequencing, particularly in advancing cancer diagnostics and improving outcomes in clinical settings.

WindMIL Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies for cancer treatment. Established in 2015 and based in Baltimore, Maryland, the company specializes in translating insights from bone marrow immunology into effective therapeutic solutions. WindMIL Therapeutics utilizes its proprietary platform to create a new class of cell therapies known as Marrow Infiltrating Lymphocytes (MILs), which are derived from memory T cells found in the bone marrow. These therapies leverage re-activated T-cells that are typically dormant, harnessing the unique immunologic properties of the bone marrow to enhance cancer immunotherapy. Through its advancements, WindMIL Therapeutics aims to provide life-saving treatments for cancer patients, addressing a critical need in oncology.

Celtaxsys, Inc. is a clinical-stage biopharmaceutical company based in Atlanta, Georgia, founded in 2007. The company specializes in the discovery and development of novel therapeutics aimed at treating inflammatory diseases, including cystic fibrosis and moderately severe acne. Its lead product, CTX-4430, is a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells. Celtaxsys also focuses on manipulating immune cell migration and activation to develop treatments for cancer, inflammatory conditions, and autoimmune diseases. Through its innovative approach, the company aims to provide effective therapies for patients suffering from rare and serious inflammatory disorders.

Fractyl Health Inc. is a medical technology company dedicated to developing innovative solutions for the treatment of metabolic diseases, particularly type 2 diabetes and obesity. The company specializes in a minimally invasive procedure known as Revita DMR, or duodenal mucosal resurfacing therapy, which rejuvenates the lining of the duodenum through hydrothermal ablation. This approach aims to remove excessive layers of the duodenal mucosa that accumulate due to unhealthy diets, thereby addressing the root causes of metabolic disorders. Founded in 2010 and based in Lexington, Massachusetts, Fractyl Health seeks to redefine the treatment landscape from chronic management to durable, disease-modifying therapies, ultimately enhancing patient health and reducing the burden on healthcare systems.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing etripamil, a novel calcium channel blocker designed for the treatment of various cardiovascular conditions. Etripamil is a rapid-onset nasal spray intended for self-administration to terminate episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently conducting Phase III clinical trials for etripamil in the United States and Canada, specifically targeting PSVT, as well as ongoing Phase II trials for patients with atrial fibrillation experiencing a rapid ventricular rate. Founded in 2003 and headquartered in Montréal, Canada, Milestone Pharmaceuticals aims to address unmet needs in the treatment of transient cardiovascular conditions such as atrial arrhythmias and angina.

Sebacia, Inc. is a medical device company based in Duluth, Georgia, specializing in light-based therapies for dermatological conditions, particularly acne. Founded in 2008, Sebacia aims to provide innovative alternatives to traditional topical and systemic drugs used to treat acne. The company's technology utilizes a formulation of gold microparticles that are applied to the skin and subsequently treated with a standard dermatology laser. This method selectively targets the skin structures involved in acne, addressing unmet needs in dermatology. Sebacia's patented technology was initially developed at Rice University and further advanced in collaboration with researchers at the Wellman Center of Photomedicine at Massachusetts General Hospital.

Iterum Therapeutics plc is a clinical-stage pharmaceutical company based in Dublin, Ireland, focused on developing innovative anti-infectives to address the pressing issue of multi-drug resistant pathogens. Founded in 2015, the company is advancing sulopenem, a novel penem anti-infective compound that is currently undergoing Phase III clinical trials. Sulopenem is designed for both oral and intravenous use and aims to treat various serious infections, including uncomplicated and complicated urinary tract infections as well as complicated intra-abdominal infections. The company’s mission is to significantly improve the lives of patients affected by serious and life-threatening diseases by providing effective solutions to antibiotic resistance.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through the development of highly sensitive tests that identify and characterize circulating tumor cells (CTCs) using minimally invasive blood samples. Founded in 2008, the company’s platform enables the profiling of single-cell phenotypes and genotypes, providing detailed information on biomarker expression levels, morphologic characteristics, and genetic changes. Epic Sciences offers the Oncotype DX AR-V7 Nucleus Detect test specifically for patients with metastatic castration-resistant prostate cancer, as well as biopharma solutions. The company collaborates with biotechnology and pharmaceutical firms, major cancer centers, and renowned research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and guide treatment decisions.

ChromaCode Inc., established in 2012 and based in Carlsbad, California, specializes in molecular diagnostics. The company develops innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) using technology licensed from Caltech. ChromaCode's core products are software, reagents, and assays that enhance the multiplexing capabilities of quantitative PCR (qPCR) instruments by fivefold. Additionally, they offer molecular assays and software for various applications such as personalized medicine and pharmaceutical research. One of their notable products is the HDPCR Tick-Borne Pathogen Panel, a multiplex PCR test detecting common tick-borne pathogens in a single assay. ChromaCode's technology focuses on improving signal processing from life science instrumentation, enabling cost-effective testing of multiple targets simultaneously while integrating into existing laboratory workflows.

Dicerna Pharmaceuticals is a biopharmaceutical company that specializes in the discovery and development of RNA interference (RNAi)-based therapeutics. The company focuses on innovative treatments for rare inherited liver diseases, viral infections, chronic liver diseases, and cardiometabolic conditions. Utilizing its proprietary GalXC RNAi technology platform, Dicerna is advancing several key product candidates, including nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B, and programs targeting genetic liver diseases and cardiovascular conditions. Founded in 2007 and headquartered in Lexington, Massachusetts, Dicerna has established strategic collaborations with major pharmaceutical firms to enhance its research and development efforts.

Adynxx is a biopharmaceutical company established in San Francisco, California, in 2007. It specializes in developing innovative drugs for pain management. The company's primary focus is on creating novel therapeutics called transcription factor decoys to address unmet needs in treating pain and inflammation. Adynxx has two key drug candidates: brivoligide, currently in Phase 2 trials for postoperative pain prevention, and AYX2, a preclinical candidate targeting chronic inflammatory and neuropathic pain syndromes. Additionally, the company offers other therapeutic programs aimed at providing long-term relief for mature chronic pain syndromes.

Axial Biotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. Utilizing a microbiome discovery platform, the company targets the gut-brain axis to create innovative therapies aimed at improving the quality of life for patients suffering from neurological conditions. Founded in 2013 and headquartered in Waltham, Massachusetts, Axial Biotherapeutics is in the clinical stage of its development, working to advance its pipeline of novel CNS therapeutics.

Axial Biotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. Utilizing a microbiome discovery platform, the company targets the gut-brain axis to create innovative therapies aimed at improving the quality of life for patients suffering from neurological conditions. Founded in 2013 and headquartered in Waltham, Massachusetts, Axial Biotherapeutics is in the clinical stage of its development, working to advance its pipeline of novel CNS therapeutics.

ReVision Optics, Inc. is a company that specializes in designing, manufacturing, and delivering implantable products aimed at treating presbyopia, a condition associated with the natural aging process that affects near vision. The company's flagship product, the PRESBYLENS Corneal Inlay, offers a patented refractive surgery solution that enhances visual acuity for individuals experiencing age-related vision loss. Founded in 1996 and based in Lake Forest, California, ReVision Optics serves ophthalmology professionals, providing them with advanced technology to improve patient outcomes. Originally established as IntraLens Vision, Inc., the company rebranded to its current name in 2005, reflecting its focus on innovative optical solutions.

Gene Sciences, Inc. is a biotechnology company based in San Diego, California, incorporated in 2016. The company focuses on the development of innovative DNA-targeted therapeutics aimed at modulating gene expression for the treatment of various human diseases. Gene Sciences serves customers primarily in the United States and is dedicated to advancing solutions that address unmet medical needs through its proprietary therapeutic approaches.

ROX Medical, Inc. is a medical device company based in San Clemente, California, that specializes in developing interventional vascular therapy devices aimed at treating uncontrolled hypertension and chronic obstructive pulmonary disease (COPD). Founded in 2003, the company has introduced the ROX Coupler, a device designed to lower blood pressure in patients with treatment-resistant hypertension by reducing peripheral vascular resistance and enhancing vascular compliance. Additionally, this device aims to improve respiratory function in COPD patients by facilitating better oxygen delivery to tissues, thus alleviating symptoms and enhancing exercise tolerance. ROX Medical is focused on delivering innovative solutions to improve patient outcomes in both hypertension and respiratory health.

Bionano Genomics, Inc. is a biotechnology company focused on genome mapping and analysis. It develops and markets the Saphyr system, an advanced platform designed for ultra-sensitive and specific detection of structural variations in DNA, such as insertions, deletions, and translocations, which are often linked to genetic disorders and diseases, including cancer. The Saphyr system employs optical genome mapping technology, allowing for direct visualization and analysis of long DNA molecules without relying on sequencing. This capability provides researchers and clinicians with critical insights into the structural variations within genomes, enhancing the understanding of disease mechanisms and supporting the development of personalized treatment strategies. Bionano Genomics also offers essential reagents and data solutions, including Bionano prep kits, labeling kits, and software tools for comprehensive experiment management. Its products are primarily sold to academic and governmental research laboratories, as well as pharmaceutical, biotechnology, and contract research organizations across multiple regions, including North America, Europe, and Asia. Founded in 2003 and headquartered in San Diego, California, the company was previously known as BioNano Genomics, Inc. until its name change in July 2018.

Miramar Labs is a medical device company based in Sunnyvale, California, founded in 2006. It specializes in developing non-invasive treatments for primary axillary hyperhidrosis, which is excessive sweating in the underarm area. The company's flagship product, the miraDry System, employs microwave energy to selectively target and permanently eliminate sweat and odor glands, providing a long-lasting solution for individuals suffering from this condition. By addressing hyperhidrosis, Miramar Labs aims to enhance the confidence and quality of life for its users. The miraDry System is specifically designed for underarm treatment and is not intended for use on other areas of the body, such as the hands and feet.

Obalon Therapeutics, Inc. is a medical device company based in Carlsbad, California, that specializes in developing and commercializing innovative solutions for obesity treatment. The company's flagship product, the Obalon Balloon System, is designed to assist weight loss in obese patients through a swallowable capsule that contains an inflatable balloon. This system includes the Obalon Navigation System, which utilizes hardware and software to monitor the balloon's placement, as well as the Obalon Touch Inflation Dispenser, a semi-automated device for inflating the balloon post-placement. Founded in 2008, Obalon emphasizes engineering excellence and close collaboration with clinicians to create high-quality medical products aimed at improving patient outcomes. As of early 2020, the company operated three retail treatment centers in California, underscoring its commitment to providing accessible weight loss solutions.

Bionano Genomics, Inc. is a biotechnology company focused on genome mapping and analysis. It develops and markets the Saphyr system, an advanced platform designed for ultra-sensitive and specific detection of structural variations in DNA, such as insertions, deletions, and translocations, which are often linked to genetic disorders and diseases, including cancer. The Saphyr system employs optical genome mapping technology, allowing for direct visualization and analysis of long DNA molecules without relying on sequencing. This capability provides researchers and clinicians with critical insights into the structural variations within genomes, enhancing the understanding of disease mechanisms and supporting the development of personalized treatment strategies. Bionano Genomics also offers essential reagents and data solutions, including Bionano prep kits, labeling kits, and software tools for comprehensive experiment management. Its products are primarily sold to academic and governmental research laboratories, as well as pharmaceutical, biotechnology, and contract research organizations across multiple regions, including North America, Europe, and Asia. Founded in 2003 and headquartered in San Diego, California, the company was previously known as BioNano Genomics, Inc. until its name change in July 2018.

Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, specifically vertebral compression fractures and degenerative disc diseases. Its product offerings include the Kiva system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for treating pathological vertebral compression fractures. Additionally, Benvenue Medical has introduced the Luna 3D, an expandable interbody fusion system suitable for various surgical approaches. The company serves a diverse customer base across the United States, Canada, Belgium, France, and Germany. Founded in 2004, Benvenue Medical is headquartered in Santa Clara, California, and is focused on developing innovative surgical solutions that enhance patient outcomes and restore spinal alignment.

Singular Genomics is a life science technology company that develops innovative sequencing platforms. Its core product, the Singular Sequencing Engine, powers two integrated solutions: G4 for next-generation sequencing (NGS) markets, offering high accuracy and speed; and PX, which combines single-cell analysis, spatial analysis, genomics, and proteomics in one versatile multi-omics instrument. These products aim to empower researchers and clinicians across diverse fields such as basic biology, oncology, immunology, and more.

Fractyl Health Inc. is a medical technology company dedicated to developing innovative solutions for the treatment of metabolic diseases, particularly type 2 diabetes and obesity. The company specializes in a minimally invasive procedure known as Revita DMR, or duodenal mucosal resurfacing therapy, which rejuvenates the lining of the duodenum through hydrothermal ablation. This approach aims to remove excessive layers of the duodenal mucosa that accumulate due to unhealthy diets, thereby addressing the root causes of metabolic disorders. Founded in 2010 and based in Lexington, Massachusetts, Fractyl Health seeks to redefine the treatment landscape from chronic management to durable, disease-modifying therapies, ultimately enhancing patient health and reducing the burden on healthcare systems.

Kona Medical, Inc. is a medical technology company that specializes in developing a non-invasive ultrasound-based therapy system aimed at treating hypertension and related disorders. Established in 2009 by Dr. Michael Gertner, the company focuses on addressing the challenges posed by drug-resistant hypertension through innovative approaches, particularly renal artery denervation. Its flagship product, Surround Sound, employs ultrasound imaging to precisely guide the delivery of focused ultrasound energy for renal denervation, offering a less invasive alternative to traditional treatments. Based in Issaquah, Washington, Kona Medical integrates Dr. Gertner's inventions with assets from Therus Corporation, enhancing its capabilities in therapeutic focused ultrasound.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.

Xagenic Inc., based in Toronto, Canada, specializes in developing molecular diagnostics technology for rapid, decentralized testing. Their aim is to empower clinicians with on-demand, near-patient molecular testing capabilities, enabling timely treatment decisions and improving patient care while reducing healthcare costs. Xagenic's platform detects nucleic acids from clinical samples without the need for enzymes, delivering results in just 20 minutes. This allows for widespread diagnostic testing outside of traditional clinical laboratories, initially focusing on infectious disease tests.

Sebacia, Inc. is a medical device company based in Duluth, Georgia, specializing in light-based therapies for dermatological conditions, particularly acne. Founded in 2008, Sebacia aims to provide innovative alternatives to traditional topical and systemic drugs used to treat acne. The company's technology utilizes a formulation of gold microparticles that are applied to the skin and subsequently treated with a standard dermatology laser. This method selectively targets the skin structures involved in acne, addressing unmet needs in dermatology. Sebacia's patented technology was initially developed at Rice University and further advanced in collaboration with researchers at the Wellman Center of Photomedicine at Massachusetts General Hospital.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing etripamil, a novel calcium channel blocker designed for the treatment of various cardiovascular conditions. Etripamil is a rapid-onset nasal spray intended for self-administration to terminate episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently conducting Phase III clinical trials for etripamil in the United States and Canada, specifically targeting PSVT, as well as ongoing Phase II trials for patients with atrial fibrillation experiencing a rapid ventricular rate. Founded in 2003 and headquartered in Montréal, Canada, Milestone Pharmaceuticals aims to address unmet needs in the treatment of transient cardiovascular conditions such as atrial arrhythmias and angina.

Celtaxsys, Inc. is a clinical-stage biopharmaceutical company based in Atlanta, Georgia, founded in 2007. The company specializes in the discovery and development of novel therapeutics aimed at treating inflammatory diseases, including cystic fibrosis and moderately severe acne. Its lead product, CTX-4430, is a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells. Celtaxsys also focuses on manipulating immune cell migration and activation to develop treatments for cancer, inflammatory conditions, and autoimmune diseases. Through its innovative approach, the company aims to provide effective therapies for patients suffering from rare and serious inflammatory disorders.

Twelve manufactures medical devices. It was formerly known as Foundry Newco XII, Inc. The company was incorporated in 2009 and is based in Menlo Park, California.

aTyr Pharma, Inc., established in 2005 and headquartered in San Diego, California, is a biotherapeutics company dedicated to discovering and developing innovative medicines based on novel immunological pathways. The company's primary focus is efzofitimod (formerly ATYR1923), a fusion protein currently in clinical trials for treating interstitial lung diseases by modulating immune engagement through the neuropilin-2 receptor. aTyr Pharma has collaborations with academic institutions and industry partners, including the University of Nebraska Medical Center, CSL Behring, Boston Children's Hospital, Kyorin Pharmaceutical Co., Ltd., and the Medical University of South Carolina, to advance its pipeline of immunomodulatory therapeutics derived from tRNA synthetases. The company is backed by prominent life sciences investors such as Alta Partners, Cardinal Partners, Domain Associates, and Polaris Ventures.

Obalon Therapeutics, Inc. is a medical device company based in Carlsbad, California, that specializes in developing and commercializing innovative solutions for obesity treatment. The company's flagship product, the Obalon Balloon System, is designed to assist weight loss in obese patients through a swallowable capsule that contains an inflatable balloon. This system includes the Obalon Navigation System, which utilizes hardware and software to monitor the balloon's placement, as well as the Obalon Touch Inflation Dispenser, a semi-automated device for inflating the balloon post-placement. Founded in 2008, Obalon emphasizes engineering excellence and close collaboration with clinicians to create high-quality medical products aimed at improving patient outcomes. As of early 2020, the company operated three retail treatment centers in California, underscoring its commitment to providing accessible weight loss solutions.

CoLucid Pharmaceuticals, Inc. is a biotechnology company dedicated to developing therapies for central nervous system disorders. The company focuses on innovative treatments for migraine headaches and other neurological conditions. It is advancing COL-144, a neurally acting anti-migraine agent aimed at effectively treating migraines. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform that generates new chemical entities for addressing a range of conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Established in 2005, CoLucid Pharmaceuticals is headquartered in Research Triangle Park, North Carolina.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, specializing in women's health diagnostics. Founded in 2008, it focuses on developing innovative diagnostic tests that aid in the early prediction of a woman's individualized risk for complications during pregnancy, including premature birth, preeclampsia, and gestational diabetes. Sera's proprietary proteomics and bioinformatics platform enables the discovery and commercialization of blood-based biomarker tests, which provide critical information to healthcare providers. Notably, the company's PreTRM® Test assesses the risk of spontaneous premature delivery, facilitating timely interventions for at-risk patients. By addressing the healthcare challenges associated with pregnancy complications, Sera aims to enhance maternal and neonatal health while reducing overall healthcare costs.

Bionano Genomics, Inc. is a biotechnology company focused on genome mapping and analysis. It develops and markets the Saphyr system, an advanced platform designed for ultra-sensitive and specific detection of structural variations in DNA, such as insertions, deletions, and translocations, which are often linked to genetic disorders and diseases, including cancer. The Saphyr system employs optical genome mapping technology, allowing for direct visualization and analysis of long DNA molecules without relying on sequencing. This capability provides researchers and clinicians with critical insights into the structural variations within genomes, enhancing the understanding of disease mechanisms and supporting the development of personalized treatment strategies. Bionano Genomics also offers essential reagents and data solutions, including Bionano prep kits, labeling kits, and software tools for comprehensive experiment management. Its products are primarily sold to academic and governmental research laboratories, as well as pharmaceutical, biotechnology, and contract research organizations across multiple regions, including North America, Europe, and Asia. Founded in 2003 and headquartered in San Diego, California, the company was previously known as BioNano Genomics, Inc. until its name change in July 2018.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, specializing in women's health diagnostics. Founded in 2008, it focuses on developing innovative diagnostic tests that aid in the early prediction of a woman's individualized risk for complications during pregnancy, including premature birth, preeclampsia, and gestational diabetes. Sera's proprietary proteomics and bioinformatics platform enables the discovery and commercialization of blood-based biomarker tests, which provide critical information to healthcare providers. Notably, the company's PreTRM® Test assesses the risk of spontaneous premature delivery, facilitating timely interventions for at-risk patients. By addressing the healthcare challenges associated with pregnancy complications, Sera aims to enhance maternal and neonatal health while reducing overall healthcare costs.

Miramar Labs is a medical device company based in Sunnyvale, California, founded in 2006. It specializes in developing non-invasive treatments for primary axillary hyperhidrosis, which is excessive sweating in the underarm area. The company's flagship product, the miraDry System, employs microwave energy to selectively target and permanently eliminate sweat and odor glands, providing a long-lasting solution for individuals suffering from this condition. By addressing hyperhidrosis, Miramar Labs aims to enhance the confidence and quality of life for its users. The miraDry System is specifically designed for underarm treatment and is not intended for use on other areas of the body, such as the hands and feet.

Zyga Technology, Inc. is a medical device company focused on the research, design, development, and commercialization of minimally invasive products aimed at addressing underserved conditions of the lumbar spine. Founded in 2008 and headquartered in Minnetonka, Minnesota, the company offers the SImmetry Sacroiliac Joint Fusion System, which provides a surgical solution for sacroiliac joint fusion in patients with conditions such as sacroiliac joint disruptions and degenerative sacroiliitis. Additionally, Zyga is developing the Glyder Facet Restoration System, an investigational device intended to treat chronic facetogenic pain. The company is supported by a team of experienced engineers, marketing personnel, and management dedicated to advancing medical devices in the spine industry. Zyga Technology operates as a subsidiary of RTI Surgical, Inc.

VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company based in Seattle, Washington, founded in 2006. The company specializes in developing and commercializing immunotherapies that target Toll-like Receptor 8 (TLR8) for the treatment of cancer, respiratory, and inflammatory diseases. Its lead investigational drug, Motolimod, aims to activate the immune system by stimulating myeloid dendritic cells, monocytes, and natural killer cells to combat cancer. VentiRx's product pipeline includes VTX-2337, a small molecule TLR8 agonist targeting solid tumors and various cancers, as well as VTX-1463 for treating allergies. The company also explores TLR8 antagonists for autoimmune diseases and other compounds that may serve as vaccine adjuvants. VentiRx has a strategic collaboration with Celgene Corporation to further its research and development efforts.

Colorescience, Inc. is a Carlsbad, California-based company that specializes in producing and selling mineral-based cosmetics and sunscreen products. Founded in 2000, Colorescience offers a range of products including treatment solutions for pigmentation, redness, dark circles, and signs of aging, as well as products designed for sensitive, oily, and dry skin. Its offerings include UV protectors, primers, foundations, and enhancers, all formulated with high-quality, dermatologist-recommended ingredients such as minerals, antioxidants, and botanicals. The company differentiates itself in the luxury aesthetic makeup market by emphasizing efficacy, convenience, and simplicity of use. Colorescience distributes its products through a network of licensed physicians, luxury spas, retailers, and online platforms, with a commitment to addressing skin health and reducing the risk of skin cancer.

Fractyl Health Inc. is a medical technology company dedicated to developing innovative solutions for the treatment of metabolic diseases, particularly type 2 diabetes and obesity. The company specializes in a minimally invasive procedure known as Revita DMR, or duodenal mucosal resurfacing therapy, which rejuvenates the lining of the duodenum through hydrothermal ablation. This approach aims to remove excessive layers of the duodenal mucosa that accumulate due to unhealthy diets, thereby addressing the root causes of metabolic disorders. Founded in 2010 and based in Lexington, Massachusetts, Fractyl Health seeks to redefine the treatment landscape from chronic management to durable, disease-modifying therapies, ultimately enhancing patient health and reducing the burden on healthcare systems.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through the development of highly sensitive tests that identify and characterize circulating tumor cells (CTCs) using minimally invasive blood samples. Founded in 2008, the company’s platform enables the profiling of single-cell phenotypes and genotypes, providing detailed information on biomarker expression levels, morphologic characteristics, and genetic changes. Epic Sciences offers the Oncotype DX AR-V7 Nucleus Detect test specifically for patients with metastatic castration-resistant prostate cancer, as well as biopharma solutions. The company collaborates with biotechnology and pharmaceutical firms, major cancer centers, and renowned research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and guide treatment decisions.

Xagenic Inc., based in Toronto, Canada, specializes in developing molecular diagnostics technology for rapid, decentralized testing. Their aim is to empower clinicians with on-demand, near-patient molecular testing capabilities, enabling timely treatment decisions and improving patient care while reducing healthcare costs. Xagenic's platform detects nucleic acids from clinical samples without the need for enzymes, delivering results in just 20 minutes. This allows for widespread diagnostic testing outside of traditional clinical laboratories, initially focusing on infectious disease tests.

Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, specifically vertebral compression fractures and degenerative disc diseases. Its product offerings include the Kiva system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for treating pathological vertebral compression fractures. Additionally, Benvenue Medical has introduced the Luna 3D, an expandable interbody fusion system suitable for various surgical approaches. The company serves a diverse customer base across the United States, Canada, Belgium, France, and Germany. Founded in 2004, Benvenue Medical is headquartered in Santa Clara, California, and is focused on developing innovative surgical solutions that enhance patient outcomes and restore spinal alignment.

Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, specializing in the development and commercialization of therapeutics for ear-related diseases and disorders. The company offers OTIPRIO, a ciprofloxacin otic suspension designed for use during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-exposure formulation of dexamethasone for treating Ménière’s disease; OTO-313, aimed at treating tinnitus; and OTO-413, which targets cochlear synaptopathy and speech-in-noise hearing difficulties. Additionally, the company is developing OTO-510, an otoprotectant intended to prevent cisplatin-induced hearing loss, and OTO-6XX, which aims to induce hair cell regeneration for severe hearing loss. Otonomy leverages a proprietary formulation platform that allows for sustained drug exposure from a single administration, positioning itself as a leader in localized drug delivery for otic disorders. Founded in 2008, Otonomy focuses its operations primarily in the United States.

Smart Medical Systems Ltd. is a medical device company based in Ra’anana, Israel, specializing in gastroenterology and gastrointestinal (GI) endoscopy. The company develops innovative devices aimed at enhancing the practice of GI endoscopy, particularly through its proprietary balloon technology. Its flagship product, the G-EYE endoscope, facilitates Controlled Withdrawal during colonoscopy, improving visibility and efficiency in detecting polyps. In addition to the G-EYE, Smart Medical Systems offers several devices, including the NaviAid Platform, which addresses challenges in GI procedures, and various balloon devices for ileoscopy and colonoscopy. The company is committed to providing cost-effective solutions that benefit both healthcare professionals and patients, and it serves its customers through distributors in the United States and Europe. Smart Medical Systems is also ISO 13485:2003 certified, ensuring a high standard of quality in its product offerings.

Sequent Medical is a privately-held medical device company focused on developing innovative catheter-based neurovascular technologies. Founded in 2006, the company is headquartered in Aliso Viejo, California, with additional operations in Bonn, Germany. Sequent Medical has invented and developed Microbraid technology to create the WEB Aneurysm Embolization System, a versatile treatment option for both ruptured and unruptured intracranial aneurysms. The WEB system has received CE mark approval and has been used to treat nearly 600 aneurysms in Europe, Latin America, and New Zealand. However, it is not available for sale or use in the United States.

Evofem Biosciences is a biopharmaceutical company based in San Diego, California, focused on addressing unmet needs in women's sexual and reproductive health. The company has developed Phexxi, the first and only hormone-free prescription vaginal gel approved in the United States for pregnancy prevention. In addition to Phexxi, Evofem is also working on EVO100, a vaginal pH regulator aimed at preventing the urogenital transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. Through its innovative products, Evofem Biosciences aims to enhance reproductive health care options for women.

Neothetics, Inc. was a clinical-stage specialty pharmaceutical company focused on developing therapeutics for the aesthetic market. Founded in 2007 and headquartered in San Diego, California, the company specialized in innovative treatments aimed at improving aesthetic outcomes. Its lead product candidate, LIPO-202, was an injectable formulation designed to reduce localized fat deposits under the chin and address central abdominal bulging in non-obese patients. Originally established as Lipothera, Inc., the company underwent a name change in August 2014, reflecting its commitment to aesthetic medicine. Neothetics was acquired by Evofem Biosciences, Inc. in a reverse merger transaction in January 2018.

Atara Biotherapeutics, Inc. is a biotechnology company focused on developing off-the-shelf T-cell immunotherapies for patients with cancer, autoimmune diseases, and viral infections. The company is advancing tabelecleucel, a T-cell immunotherapy currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, as well as other related hematologic and solid tumors, including nasopharyngeal carcinoma. Atara is also working on next-generation CAR T immunotherapies targeting various indications, including ATA2271 and ATA3271 for mesothelin, and ATA2431 and ATA3219 for B-cell lymphomas. Additionally, its pipeline includes ATA188 for multiple sclerosis and several other candidates for conditions such as acute myeloid leukemia and cytomegalovirus. Founded in 2012, Atara Biotherapeutics is headquartered in South San Francisco, California, and collaborates with leading academic institutions to enhance its research and development efforts.

Atara Biotherapeutics, Inc. is a biotechnology company focused on developing off-the-shelf T-cell immunotherapies for patients with cancer, autoimmune diseases, and viral infections. The company is advancing tabelecleucel, a T-cell immunotherapy currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, as well as other related hematologic and solid tumors, including nasopharyngeal carcinoma. Atara is also working on next-generation CAR T immunotherapies targeting various indications, including ATA2271 and ATA3271 for mesothelin, and ATA2431 and ATA3219 for B-cell lymphomas. Additionally, its pipeline includes ATA188 for multiple sclerosis and several other candidates for conditions such as acute myeloid leukemia and cytomegalovirus. Founded in 2012, Atara Biotherapeutics is headquartered in South San Francisco, California, and collaborates with leading academic institutions to enhance its research and development efforts.

RightCare Solutions is a healthcare technology company based in Horsham, Pennsylvania, established in 2011. The company focuses on enhancing the discharge planning process for hospitals, insurers, and homecare agencies through its proprietary Discharge Decision Support System, known as D2S2. This evidence-based platform enables healthcare providers to predict and identify high-risk patients at the time of admission, thereby improving patient outcomes and the overall quality of care. By addressing the challenges associated with 30-day readmissions, RightCare Solutions aims to alleviate the financial and operational burdens on the healthcare system, ensuring a more effective continuum of care for patients.

Novadigm Therapeutics is a biotechnology company focused on developing vaccines to protect patients from fungal and bacterial infections. Founded in 2005 and headquartered in Grand Forks, North Dakota, the company is known for its innovative products such as NDV-3, which has shown preclinical efficacy in reducing disease severity caused by these pathogens. Additionally, Novadigm has developed Als3, an antigen vaccine that targets systemic and mucosal candidal infections by utilizing a recombinant form of the Als3 surface protein. This protein plays a crucial role in the adherence and invasion of human endothelial cells, aiming to enhance the immune response and provide patients with proactive protection against infections.

Bionano Genomics, Inc. is a biotechnology company focused on genome mapping and analysis. It develops and markets the Saphyr system, an advanced platform designed for ultra-sensitive and specific detection of structural variations in DNA, such as insertions, deletions, and translocations, which are often linked to genetic disorders and diseases, including cancer. The Saphyr system employs optical genome mapping technology, allowing for direct visualization and analysis of long DNA molecules without relying on sequencing. This capability provides researchers and clinicians with critical insights into the structural variations within genomes, enhancing the understanding of disease mechanisms and supporting the development of personalized treatment strategies. Bionano Genomics also offers essential reagents and data solutions, including Bionano prep kits, labeling kits, and software tools for comprehensive experiment management. Its products are primarily sold to academic and governmental research laboratories, as well as pharmaceutical, biotechnology, and contract research organizations across multiple regions, including North America, Europe, and Asia. Founded in 2003 and headquartered in San Diego, California, the company was previously known as BioNano Genomics, Inc. until its name change in July 2018.

Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, specializing in the development and commercialization of therapeutics for ear-related diseases and disorders. The company offers OTIPRIO, a ciprofloxacin otic suspension designed for use during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-exposure formulation of dexamethasone for treating Ménière’s disease; OTO-313, aimed at treating tinnitus; and OTO-413, which targets cochlear synaptopathy and speech-in-noise hearing difficulties. Additionally, the company is developing OTO-510, an otoprotectant intended to prevent cisplatin-induced hearing loss, and OTO-6XX, which aims to induce hair cell regeneration for severe hearing loss. Otonomy leverages a proprietary formulation platform that allows for sustained drug exposure from a single administration, positioning itself as a leader in localized drug delivery for otic disorders. Founded in 2008, Otonomy focuses its operations primarily in the United States.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.

Applied Proteomics, Inc., founded in 2006 and headquartered in San Diego, California, specializes in developing noninvasive and blood-based tests for monitoring and early detection of disease. The company focuses on protein biomarkers, offering a proteomics platform that enables the discovery and application of these biomarkers in diagnostics and personalized medicine to enhance healthcare outcomes. One of their key products is the SimpliPro Colon test, which provides diagnostic solutions based on protein interactions within the body.

Dicerna Pharmaceuticals is a biopharmaceutical company that specializes in the discovery and development of RNA interference (RNAi)-based therapeutics. The company focuses on innovative treatments for rare inherited liver diseases, viral infections, chronic liver diseases, and cardiometabolic conditions. Utilizing its proprietary GalXC RNAi technology platform, Dicerna is advancing several key product candidates, including nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B, and programs targeting genetic liver diseases and cardiovascular conditions. Founded in 2007 and headquartered in Lexington, Massachusetts, Dicerna has established strategic collaborations with major pharmaceutical firms to enhance its research and development efforts.

aTyr Pharma, Inc., established in 2005 and headquartered in San Diego, California, is a biotherapeutics company dedicated to discovering and developing innovative medicines based on novel immunological pathways. The company's primary focus is efzofitimod (formerly ATYR1923), a fusion protein currently in clinical trials for treating interstitial lung diseases by modulating immune engagement through the neuropilin-2 receptor. aTyr Pharma has collaborations with academic institutions and industry partners, including the University of Nebraska Medical Center, CSL Behring, Boston Children's Hospital, Kyorin Pharmaceutical Co., Ltd., and the Medical University of South Carolina, to advance its pipeline of immunomodulatory therapeutics derived from tRNA synthetases. The company is backed by prominent life sciences investors such as Alta Partners, Cardinal Partners, Domain Associates, and Polaris Ventures.

ReVision Optics, Inc. is a company that specializes in designing, manufacturing, and delivering implantable products aimed at treating presbyopia, a condition associated with the natural aging process that affects near vision. The company's flagship product, the PRESBYLENS Corneal Inlay, offers a patented refractive surgery solution that enhances visual acuity for individuals experiencing age-related vision loss. Founded in 1996 and based in Lake Forest, California, ReVision Optics serves ophthalmology professionals, providing them with advanced technology to improve patient outcomes. Originally established as IntraLens Vision, Inc., the company rebranded to its current name in 2005, reflecting its focus on innovative optical solutions.

Veracyte, Inc. is a genomic diagnostics company based in South San Francisco, California, that specializes in providing advanced diagnostic solutions for cancer and other diseases. Its product offerings include the Afirma Genomic Sequencing Classifier, which helps identify benign thyroid nodules, the Percepta Genomic Sequencing Classifier for lung cancer, and the Envisia Genomic Classifier for distinguishing idiopathic pulmonary fibrosis from other interstitial lung diseases. Additionally, Veracyte offers the Prosigna Breast Cancer Prognostic Gene Signature Assay, which assesses the risk of distant recurrence in breast cancer patients. The company's tests leverage advances in genomic science to reduce the need for invasive procedures, thereby facilitating timely and accurate treatment decisions. Veracyte has established collaborations with Johnson & Johnson Innovation and Loxo Oncology to enhance its diagnostic capabilities and develop targeted therapies for genetically defined cancers. Since its incorporation in 2006 and subsequent name change in 2008, Veracyte has aimed to improve patient care through innovative genomic testing.

Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.

ReVision Optics, Inc. is a company that specializes in designing, manufacturing, and delivering implantable products aimed at treating presbyopia, a condition associated with the natural aging process that affects near vision. The company's flagship product, the PRESBYLENS Corneal Inlay, offers a patented refractive surgery solution that enhances visual acuity for individuals experiencing age-related vision loss. Founded in 1996 and based in Lake Forest, California, ReVision Optics serves ophthalmology professionals, providing them with advanced technology to improve patient outcomes. Originally established as IntraLens Vision, Inc., the company rebranded to its current name in 2005, reflecting its focus on innovative optical solutions.

Afferent Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, focused on developing innovative medicines for chronic pain management and neurogenic disorders. The company specializes in targeting P2X3 receptors found in nerve fibers, creating small molecule compounds designed to address conditions such as osteoarthritis, back pain, visceral pain, and neuropathy. Afferent's lead compound, AF-219, has successfully completed two Phase 1 clinical studies, positioning the company to advance its portfolio of therapeutics aimed at improving the quality of life for patients suffering from various pain-related ailments. Founded in 2009, Afferent Pharmaceuticals is dedicated to advancing the understanding and treatment of chronic pain through scientific innovation.

Atara Biotherapeutics, Inc. is a biotechnology company focused on developing off-the-shelf T-cell immunotherapies for patients with cancer, autoimmune diseases, and viral infections. The company is advancing tabelecleucel, a T-cell immunotherapy currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, as well as other related hematologic and solid tumors, including nasopharyngeal carcinoma. Atara is also working on next-generation CAR T immunotherapies targeting various indications, including ATA2271 and ATA3271 for mesothelin, and ATA2431 and ATA3219 for B-cell lymphomas. Additionally, its pipeline includes ATA188 for multiple sclerosis and several other candidates for conditions such as acute myeloid leukemia and cytomegalovirus. Founded in 2012, Atara Biotherapeutics is headquartered in South San Francisco, California, and collaborates with leading academic institutions to enhance its research and development efforts.

Achaogen, Inc. is a biopharmaceutical company based in South San Francisco, California, that specializes in the development and commercialization of antibacterial agents targeting multi-drug resistant (MDR) gram-negative infections. The company's primary focus is on plazomicin, which is intended for treating serious bacterial infections caused by MDR enterobacteriaceae, including carbapenem-resistant strains. Additionally, Achaogen is developing C-Scape, an orally-administered combination of clavulanate and ceftibuten aimed at addressing serious infections linked to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established collaborations with various organizations, including Thermo Fisher Scientific and Ionis Pharmaceuticals, to support its drug development efforts. The company was incorporated in 2002, but faced financial difficulties, leading to a Chapter 11 bankruptcy filing in 2019, which culminated in a liquidation plan approved in 2020. All of Achaogen's revenue has been derived from government contracts for research and development within the United States.

Glaukos Corporation is an ophthalmic medical technology company dedicated to developing innovative products and procedures aimed at transforming the treatment of glaucoma, a major cause of blindness worldwide. The company has pioneered Micro-Invasive Glaucoma Surgery (MIGS) to enhance traditional glaucoma management approaches. Its flagship product, the iStent, was introduced in the United States in 2012 and is designed as a micro-bypass stent that can be inserted during cataract surgery to lower intraocular pressure in adults with mild-to-moderate open-angle glaucoma. Glaukos is also advancing its product pipeline with the iStent SA, a two-stent system that utilizes a unique auto-injection inserter for standalone procedures. Founded in 1998 and headquartered in San Clemente, California, Glaukos aims to build a comprehensive portfolio of injectable micro-scale therapies to address various glaucoma disease states and progression.

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for rare seizure disorders and neuropsychiatric conditions. The company's lead product candidate, ganaxolone, functions as an allosteric modulator of GABAA receptors and is being developed in both intravenous and oral formulations for use in various patient populations, including adults and children. Ganaxolone is targeted for multiple indications, such as status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment-resistant depression. Marinus Pharmaceuticals emphasizes collaboration with healthcare professionals and partners to enhance patient care and improve the lives of those affected by these conditions. Founded in 2003 and headquartered in Radnor, Pennsylvania, the company is committed to advancing its therapeutic offerings through rigorous scientific research and development.

Evofem Biosciences is a biopharmaceutical company based in San Diego, California, focused on addressing unmet needs in women's sexual and reproductive health. The company has developed Phexxi, the first and only hormone-free prescription vaginal gel approved in the United States for pregnancy prevention. In addition to Phexxi, Evofem is also working on EVO100, a vaginal pH regulator aimed at preventing the urogenital transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. Through its innovative products, Evofem Biosciences aims to enhance reproductive health care options for women.

Neothetics, Inc. was a clinical-stage specialty pharmaceutical company focused on developing therapeutics for the aesthetic market. Founded in 2007 and headquartered in San Diego, California, the company specialized in innovative treatments aimed at improving aesthetic outcomes. Its lead product candidate, LIPO-202, was an injectable formulation designed to reduce localized fat deposits under the chin and address central abdominal bulging in non-obese patients. Originally established as Lipothera, Inc., the company underwent a name change in August 2014, reflecting its commitment to aesthetic medicine. Neothetics was acquired by Evofem Biosciences, Inc. in a reverse merger transaction in January 2018.

Regado Biosciences is a biopharmaceutical company focused on the discovery and development of aptamer-based therapeutics, specifically targeting antidote-controlled treatments. Founded in 2001 and headquartered in Durham, North Carolina, the company is known for its innovative approach to antithrombotic therapies, including its lead product, REG1, which is designed for patients experiencing acute coronary syndrome undergoing coronary revascularization procedures. Regado's research emphasizes the development of therapeutic aptamers paired with active control agents, aiming to address both arterial and venous thrombosis effectively.

Kona Medical, Inc. is a medical technology company that specializes in developing a non-invasive ultrasound-based therapy system aimed at treating hypertension and related disorders. Established in 2009 by Dr. Michael Gertner, the company focuses on addressing the challenges posed by drug-resistant hypertension through innovative approaches, particularly renal artery denervation. Its flagship product, Surround Sound, employs ultrasound imaging to precisely guide the delivery of focused ultrasound energy for renal denervation, offering a less invasive alternative to traditional treatments. Based in Issaquah, Washington, Kona Medical integrates Dr. Gertner's inventions with assets from Therus Corporation, enhancing its capabilities in therapeutic focused ultrasound.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through the development of highly sensitive tests that identify and characterize circulating tumor cells (CTCs) using minimally invasive blood samples. Founded in 2008, the company’s platform enables the profiling of single-cell phenotypes and genotypes, providing detailed information on biomarker expression levels, morphologic characteristics, and genetic changes. Epic Sciences offers the Oncotype DX AR-V7 Nucleus Detect test specifically for patients with metastatic castration-resistant prostate cancer, as well as biopharma solutions. The company collaborates with biotechnology and pharmaceutical firms, major cancer centers, and renowned research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and guide treatment decisions.

RightCare Solutions is a healthcare technology company based in Horsham, Pennsylvania, established in 2011. The company focuses on enhancing the discharge planning process for hospitals, insurers, and homecare agencies through its proprietary Discharge Decision Support System, known as D2S2. This evidence-based platform enables healthcare providers to predict and identify high-risk patients at the time of admission, thereby improving patient outcomes and the overall quality of care. By addressing the challenges associated with 30-day readmissions, RightCare Solutions aims to alleviate the financial and operational burdens on the healthcare system, ensuring a more effective continuum of care for patients.

Veracyte, Inc. is a genomic diagnostics company based in South San Francisco, California, that specializes in providing advanced diagnostic solutions for cancer and other diseases. Its product offerings include the Afirma Genomic Sequencing Classifier, which helps identify benign thyroid nodules, the Percepta Genomic Sequencing Classifier for lung cancer, and the Envisia Genomic Classifier for distinguishing idiopathic pulmonary fibrosis from other interstitial lung diseases. Additionally, Veracyte offers the Prosigna Breast Cancer Prognostic Gene Signature Assay, which assesses the risk of distant recurrence in breast cancer patients. The company's tests leverage advances in genomic science to reduce the need for invasive procedures, thereby facilitating timely and accurate treatment decisions. Veracyte has established collaborations with Johnson & Johnson Innovation and Loxo Oncology to enhance its diagnostic capabilities and develop targeted therapies for genetically defined cancers. Since its incorporation in 2006 and subsequent name change in 2008, Veracyte has aimed to improve patient care through innovative genomic testing.

Cotera, Inc. is a medical device company based in Menlo Park, California, specializing in orthopedic implants aimed at treating knee osteoarthritis. Founded in 2011, Cotera has developed a notable product, the Latella device, which is surgically attached to the femur to alleviate medial knee pain associated with osteoarthritis. This implant not only aims to provide long-term relief for patients but is also designed for easy removal, thereby preserving future treatment options. Through its innovative approach, Cotera seeks to enhance the quality of life for individuals suffering from joint pain.

Tandem Diabetes Care, Inc. is a medical device company headquartered in San Diego, California, which specializes in the design, development, and commercialization of insulin delivery systems for individuals with insulin-dependent diabetes. Its flagship product, the t:slim X2 insulin delivery system, includes a pump, a 300-unit disposable insulin cartridge, and an infusion set. The company offers advanced features such as Basal-IQ Technology and Control-IQ Technology, along with the Tandem Device Updater for software enhancements. Additionally, Tandem provides the t:connect web-based data management application and the Sugarmate mobile app to support diabetes management for users and their caregivers. Tandem Diabetes Care entered the insulin pump market in 2012 and has since expanded its product line, including the recent launch of the smaller Mobi pump and development of a tubeless pump. The majority of the company’s revenue is generated in the United States, with additional sales from other developed countries.

ROX Medical, Inc. is a medical device company based in San Clemente, California, that specializes in developing interventional vascular therapy devices aimed at treating uncontrolled hypertension and chronic obstructive pulmonary disease (COPD). Founded in 2003, the company has introduced the ROX Coupler, a device designed to lower blood pressure in patients with treatment-resistant hypertension by reducing peripheral vascular resistance and enhancing vascular compliance. Additionally, this device aims to improve respiratory function in COPD patients by facilitating better oxygen delivery to tissues, thus alleviating symptoms and enhancing exercise tolerance. ROX Medical is focused on delivering innovative solutions to improve patient outcomes in both hypertension and respiratory health.

Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology. The company specializes in developing highly differentiated drug candidates based upon a novel mechanism of action called “Gap Junction Channel Modulation.” It has developed treatments for multiple front- and back-of-the-eye diseases and disorders that would potentially alter the standard of care. In addition, the company's technologies are expected to be transferable to other acute and chronic disease indications. Ocunexus is formerly known as CoDa Therapeutics, a pharmaceutical company focused on the development and commercialization of wound care therapeutics based on gap junction modulation. The company is based in San Diego, California.

Obalon Therapeutics, Inc. is a medical device company based in Carlsbad, California, that specializes in developing and commercializing innovative solutions for obesity treatment. The company's flagship product, the Obalon Balloon System, is designed to assist weight loss in obese patients through a swallowable capsule that contains an inflatable balloon. This system includes the Obalon Navigation System, which utilizes hardware and software to monitor the balloon's placement, as well as the Obalon Touch Inflation Dispenser, a semi-automated device for inflating the balloon post-placement. Founded in 2008, Obalon emphasizes engineering excellence and close collaboration with clinicians to create high-quality medical products aimed at improving patient outcomes. As of early 2020, the company operated three retail treatment centers in California, underscoring its commitment to providing accessible weight loss solutions.

Bionano Genomics, Inc. is a biotechnology company focused on genome mapping and analysis. It develops and markets the Saphyr system, an advanced platform designed for ultra-sensitive and specific detection of structural variations in DNA, such as insertions, deletions, and translocations, which are often linked to genetic disorders and diseases, including cancer. The Saphyr system employs optical genome mapping technology, allowing for direct visualization and analysis of long DNA molecules without relying on sequencing. This capability provides researchers and clinicians with critical insights into the structural variations within genomes, enhancing the understanding of disease mechanisms and supporting the development of personalized treatment strategies. Bionano Genomics also offers essential reagents and data solutions, including Bionano prep kits, labeling kits, and software tools for comprehensive experiment management. Its products are primarily sold to academic and governmental research laboratories, as well as pharmaceutical, biotechnology, and contract research organizations across multiple regions, including North America, Europe, and Asia. Founded in 2003 and headquartered in San Diego, California, the company was previously known as BioNano Genomics, Inc. until its name change in July 2018.

Adynxx is a biopharmaceutical company established in San Francisco, California, in 2007. It specializes in developing innovative drugs for pain management. The company's primary focus is on creating novel therapeutics called transcription factor decoys to address unmet needs in treating pain and inflammation. Adynxx has two key drug candidates: brivoligide, currently in Phase 2 trials for postoperative pain prevention, and AYX2, a preclinical candidate targeting chronic inflammatory and neuropathic pain syndromes. Additionally, the company offers other therapeutic programs aimed at providing long-term relief for mature chronic pain syndromes.

Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, specifically vertebral compression fractures and degenerative disc diseases. Its product offerings include the Kiva system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for treating pathological vertebral compression fractures. Additionally, Benvenue Medical has introduced the Luna 3D, an expandable interbody fusion system suitable for various surgical approaches. The company serves a diverse customer base across the United States, Canada, Belgium, France, and Germany. Founded in 2004, Benvenue Medical is headquartered in Santa Clara, California, and is focused on developing innovative surgical solutions that enhance patient outcomes and restore spinal alignment.